bioAffinity Technologies (NASDAQ:BIAF) Trading Down 7.5% – Time to Sell?

Shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) traded down 7.5% during trading on Monday . The company traded as low as $1.57 and last traded at $1.60. 206,736 shares changed hands during trading, an increase of 3% from the average session volume of 199,892 shares. The stock had previously closed at $1.73.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Wall Street Zen cut shares of bioAffinity Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings cut shares of bioAffinity Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

bioAffinity Technologies Price Performance

The stock’s 50-day moving average price is $2.37 and its 200-day moving average price is $1.82. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.36 and a quick ratio of 1.34.

bioAffinity Technologies (NASDAQ:BIAF) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($2.40) by $1.59. The business had revenue of $1.35 million during the quarter, compared to the consensus estimate of $1.48 million. bioAffinity Technologies had a negative return on equity of 285.75% and a negative net margin of 280.53%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Sabby Management LLC acquired a new position in bioAffinity Technologies in the third quarter valued at about $719,000. J. Safra Sarasin Holding AG acquired a new position in bioAffinity Technologies in the first quarter valued at about $164,000. Geode Capital Management LLC acquired a new position in bioAffinity Technologies in the fourth quarter valued at about $36,000. Finally, Scientech Research LLC acquired a new position in bioAffinity Technologies in the third quarter valued at about $49,000. Institutional investors and hedge funds own 1.64% of the company’s stock.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.